Article Figures & Data
Tables
- Table 1
Selected factors among cases of epithelial ovarian cancer, cancer controls, and noncancer controls (%)
Cases (780) Cancer controls (2053) Noncancer controls (2570) Age (yr) <40 19 20 20 40–49 25 25 38 50–59 29 28 21 60–79 27 27 22 Parity 0 27 19 23 1–2 42 37 35 3+ 29 38 39 Oral contraceptive use (yr) 0 71 65 67 1–4 20 22 21 5+ 7 11 10 Hysterectomy 11 17 15 Age at menopausea <45 24 35 40 45–49 30 29 26 50+ 46 36 34 Mother or sister with ovarian cancer 2 <1 <1 -
a Among postmenopausal women.
-
- Table 2
Acetaminophen use and NSAID use 1 day or more per week for at least 6 months among 780 cases of epithelial ovarian cancer, 2053 cancer controls, and 2570 noncancer controlsa
Drug and use Cases Cancer controls ORb (95% CI) Noncancer controls ORb (95% CI) Acetaminophen No 750 1955 Ref. 2462 Ref. Yes 28 81 0.9 (0.6–1.4) 95 1.0 (0.6–1.5) Duration 5+ yr 18 43 1.0 (0.6–1.8) 50 1.1 (0.6–1.9) First use 10+ yr ago 7 25 0.6 (0.2–1.4) 27 0.8 (0.3–1.8) Last use <1 yr ago 26 76 0.9 (0.5–1.4) 88 1.0 (0.6–1.5) NSAIDs No 715 1833 Ref. 2278 Ref. Yes 58 195 0.8 (0.6–1.1) 256 0.7 (0.5–1.0) Duration 5+ yr 33 84 0.7 (0.4–1.1) 103 0.7 (0.4–1.2) First use 10+ yr ago 21 69 0.8 (0.5–1.3) 72 1.0 (0.6–1.6) Last use <1 yr ago 42 150 0.8 (0.5–1.1) 227 0.6 (0.4–0.9) -
a Women whose only use began within the year before admission or whose timing of use was unknown are excluded.
-
b OR, odds ratio from logistic regressions with terms for age, geography, and interview year.
-
- Table 3
Acetaminophen use and NSAID use 4 days or more per week for at least 6 months among 780 cases of epithelial ovarian cancer, 2053 cancer controls, and 2570 noncancer controlsa
Drug and use Cases Cancer controls ORb (95% CI) Noncancer controls ORb (95% CI) Acetaminophen No 765 1992 Ref. 2514 Ref. Yes 14 50 0.7 (0.4–1.3) 52 0.9 (0.5–1.6) Duration 5+ yr 10 24 0.9 (0.4–1.9) 26 1.2 (0.5–2.6) First use 10+ yr ago 5 16 0.6 (0.2–1.7) 13 1.1 (0.4–3.2) Last use <1 yr ago 13 44 0.7 (0.4–1.4) 47 0.9 (0.5–1.7) NSAIDs No 733 1870 Ref. 2338 Ref. Yes 41 160 0.7 (0.5–1.0) 207 0.7 (0.5–1.0) Duration 5+ yr 11 63 0.5 (0.2–0.9) 81 0.5 (0.3–0.9) First use 10+ yr ago 10 56 0.5 (0.2–0.9) 53 0.7 (0.3–1.3) Last use <1 yr ago 32 117 0.7 (0.5–1.1) 181 0.6 (0.4–0.9) -
a Women whose only use began within the year before admission or whose timing of use was unknown are excluded.
-
b OR, odds ratio from logistic regressions with terms for age, geography, and interview year.
-
- Table 4
Aspirin use and nonaspirin NSAID use 4 days or more per week for at least 6 months among 780 cases of epithelial ovarian cancer, 2053 cancer controls, and 2570 noncancer controlsa
Drug and use Cases Cancer controls ORb (95% CI) Noncancer controls ORb (95% CI) Aspirin No 750 1938 Ref. 2430 Ref. Yes 27 101 0.7 (0.4–1.1) 130 0.8 (0.5–1.2) Duration 5+ yr 8 51 0.4 (0.2–0.9) 67 0.5 (0.2–1.0) Nonaspirin NSAIDs No 763 1971 Ref. 2465 Ref. Yes 14 72 0.5 (0.3–0.9) 88 0.5 (0.3–0.9) Duration 5+ yr 3 12 0.4 (0.2–0.9) 15 0.6 (0.2–2.2) -
a Women whose only use began within the year before admission or whose timing of use was unknown are excluded.
-
b OR, odds ratio from logistic regressions with terms for age, geography, and interview year.
-
- Table 5
Acetaminophen use and NSAID use 1 day or more per week and 4 days or more per week for at least 6 months among 485 cases of metastatic epithelial ovarian cancer and 295 cases of nonmetastatic epithelial ovarian cancera
Use Cases ORb (95% CI) Cancer controls Noncancer controls Metastatic ovarian cancer Acetaminophen 1+ days/week No 466 Ref. Ref. 1+ days/week Yes 18 0.9 (0.5–1.5) 1.0 (0.6–1.7) 4+ days/week No 477 Ref. Ref. 4+ days/week Yes 7 0.4 (0.2–1.2) 0.7 (0.3–1.6) NSAIDs 1+ days/week No 445 Ref. Ref. 1+ days/week Yes 34 0.7 (0.5–1.0) 0.6 (0.4–0.9) 4+ days/week No 458 Ref. Ref. 4+ days/week Yes 22 0.5 (0.3–0.8) 0.5 (0.3–0.8) Nonmetastatic ovarian cancer Acetaminophen 1+ days/week No 284 Ref. Ref. 1+ days/week Yes 10 0.9 (0.4–1.8) 1.0 (0.5–1.9) 4+ days/week No 288 Ref. Ref. 4+ days/week Yes 7 1.0 (0.4–2.3) 1.3 (0.6–3.0) NSAIDs 1+ days/week No 270 Ref. Ref. 1+ days/week Yes 24 1.0 (0.6–1.6) 0.9 (0.6–1.4) 4+ days/week Yes 275 Ref. Ref. 4+ days/week Yes 19 0.9 (0.6–1.6) 0.9 (0.6–1.6) -
a Women whose only use began within the year before admission are excluded.
-
b OR, odds ratio from logistic regressions with terms for age, geography, and interview year.
-